Allarity Therapeutics, Inc. SEC filings ALLR
Allarity Therapeutics, Inc. has 403 filings in SEC EDGAR's recent list, going back to May 27, 2021. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 2, 2026 (material agreement, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Apr 24, 2026 | — |
| CORRESP | Letter to the SEC | Apr 22, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 19, 2026 | — |
| EFFECT | Filing | Dec 5, 2025 | — |
| CORRESP | Letter to the SEC | Dec 4, 2025 | — |
| EFFECT | Filing | Sep 30, 2025 | — |
| CORRESP | Letter to the SEC | Sep 30, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 29, 2025 | — |
| NT 10-Q | Notification of late filing | Aug 14, 2025 | Jun 30, 2025 |
| RW | Withdrawal of registration statement on form s-3 | Jun 24, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 20, 2025 | — |
| DRS | Filing | Jun 16, 2025 | — |
| DEFR14A | Proxy statement | Aug 20, 2024 | — |
| RW | Filing | May 8, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 27, 2024 | — |
| PRER14A | Revised preliminary proxy statement | Feb 23, 2024 | — |
| D | Filing | Feb 2, 2024 | — |
| EFFECT | Filing | Nov 29, 2023 | — |
| CORRESP | Letter to the SEC | Nov 27, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 8, 2023 | — |
| EFFECT | Filing | Oct 19, 2023 | — |
| CORRESP | Letter to the SEC | Oct 17, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 13, 2023 | — |
| D | Filing | Sep 21, 2023 | — |
| EFFECT | Filing | Jul 5, 2023 | — |
| CORRESP | Letter to the SEC | Jun 30, 2023 | — |
| CORRESP | Letter to the SEC | Jun 30, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 12, 2023 | — |
| D | Filing | Apr 28, 2023 | — |
| D | Filing | Apr 28, 2023 | — |
| EFFECT | Filing | Apr 18, 2023 | — |
| CORRESP | Letter to the SEC | Apr 17, 2023 | — |
| D | Filing | Mar 1, 2023 | — |
| NT 10-Q | Notification of late filing | Aug 15, 2022 | Jun 30, 2022 |
| EFFECT | Filing | Jun 6, 2022 | — |
| NT 10-Q | Notification of late filing | May 17, 2022 | Mar 31, 2022 |
| NT 10-K | Notification of late filing | Apr 1, 2022 | Dec 31, 2021 |
| EFFECT | Filing | Dec 20, 2021 | — |
| CORRESP | Letter to the SEC | Dec 16, 2021 | — |
| CORRESP | Letter to the SEC | Dec 16, 2021 | — |
| CERT | 8a cert | Dec 16, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 16, 2021 | — |
| 8-A12B | For registration of certain classes | Dec 13, 2021 | — |
| 425 | Form 425 | Nov 8, 2021 | — |
| 425 | Form 425 | Nov 8, 2021 | — |
| SEC STAFF LETTER | Filing | Nov 5, 2021 | — |
| EFFECT | Filing | Nov 5, 2021 | — |
| EFFECT | Filing | Nov 5, 2021 | — |
| CORRESP | Letter to the SEC | Nov 4, 2021 | — |
| CORRESP | Letter to the SEC | Nov 2, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 1, 2021 | — |
| CORRESP | Letter to the SEC | Oct 18, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 14, 2021 | — |
| CORRESP | Letter to the SEC | Oct 12, 2021 | — |
| 425 | Form 425 | Oct 8, 2021 | — |
| CORRESP | Letter to the SEC | Sep 29, 2021 | — |
| SEC STAFF LETTER | Filing | Sep 20, 2021 | — |
| UPLOAD | Letter from the SEC | Sep 20, 2021 | — |
| 425 | Form 425 | Sep 16, 2021 | — |
| 425 | Form 425 | Sep 15, 2021 | — |
| 425 | Form 425 | Aug 26, 2021 | — |
| 425 | Form 425 | Aug 23, 2021 | — |
| 425 | Form 425 | Aug 23, 2021 | — |
| 425 | Form 425 | Aug 23, 2021 | — |
| 425 | Form 425 | Aug 23, 2021 | — |
| 425 | Form 425 | Aug 20, 2021 | — |
| CORRESP | Letter to the SEC | Aug 20, 2021 | — |
| D | Filing | May 27, 2021 | — |
Showing 68 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALLR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1860657
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.